GlassScriptPhysician profile
Hugo Akabane
NPI 1982010583
$10,605.77
in general payments reported to CMS, 2019-2025
27 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,077 · 2020: $168 · 2021: $390 · 2022: $333 · 2023: $1,356 · 2024: $2,780 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,195 · Consulting Fee: $1,745 · Food and Beverage: $673 · Education: $25.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,195.00 |
| Consulting Fee | $1,745.00 |
| Food and Beverage | $673.02 |
| Education | $25.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,698.18 | 2019-2023 | Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $2,681.25 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $1,105.96 | 2022-2023 | Tecvayli |
| Celgene Corporation | $405.17 | 2021-2024 | Pomalyst, Reblozyl |
| Astellas Pharma US INC | $348.52 | 2019-2022 | |
| Abbvie INC. | $272.83 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $127.19 | 2019-2022 | |
| Eisai INC. | $124.99 | 2019 | |
| Amgen INC. | $99.95 | 2021 | |
| Kite Pharma, INC. | $92.84 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $86.80 | 2021-2023 | |
| Seagen INC. | $82.95 | 2022 | |
| Karyopharm Therapeutics INC. | $62.42 | 2021-2023 | Xpovio |
| Genentech USA, INC. | $59.30 | 2022-2023 | Venclexta, Lunsumio |
| Jazz Pharmaceuticals INC. | $50.50 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $48.93 | 2021-2023 | Brukinsa |
| Acrotech Biopharma INC. | $39.83 | 2022 | |
| Tempus Ai, INC | $29.98 | 2024 | Xt Cdx |
| Cti Biopharma Corp. | $25.84 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.94 | 2022 | |
| Dova Pharmaceuticals | $22.82 | 2021 | |
| Genzyme Corporation | $21.81 | 2020 | |
| Emmaus Medical, INC. | $21.61 | 2023 | Endari |
| Pharmacyclics LLC, An Abbvie Company | $17.36 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Verastem, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Akabane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.